AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
This brief overview contrasts index and target date retirement funds, outlining core differences and practical tips to help you choose the right option.
25,442 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Micron has bounced around the market, but its long-term growth story is coming into sharper focus. This article expla...
As 2025 closes, star bulk (sblk) enters a new chapter. This guide breaks down the Q4 2025 results, fleet strategy, ba...
RunSybil secures $40 million in a funding round led by Khosla Ventures, backing its autonomous AI agents that hack li...
As Oklo enters 2026, the Q1 earnings landscape offers clues about its path to commercialization. This guide breaks do...
Clariti unveils Clariti AI Studio, a free training program for local governments aiming to speed up permitting. The i...
Investors are always on the hunt for the next big winner. When a software stock looks beaten-down, opportunities and ...
Keel Infrastructure surged as it secured a large convertible financing to fuel AI data centers. This article breaks d...
Nvidia is teaming with Japan to build a national AI infrastructure, signaling a major shift for investors. This artic...
Explore how Permian Resources could navigate 2025 earnings, debt reduction, and growth opportunities. Learn who benef...
FRP Holdings delivered a resilient Q3 2024 performance across its diversified subsidiaries. This deep dive reviews th...
Mega-IPOs grab headlines, but what sticks after the first week? This article breaks down the five biggest IPOs in his...